Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer
- 15 December 1980
- Vol. 46 (S12) , 2922-2924
- https://doi.org/10.1002/1097-0142(19801215)46:12+<2922::aid-cncr2820461435>3.0.co;2-d
Abstract
In a consecutive series of 191 patients with advanced breast cancer, the response rate to endocrine treatment was 46/136 (34%) in estrogen receptor positive (ER+) patients, compared with 5/55 (9%) in estrogen receptor negative (ER-) patients (P < 0.01). In a retrospective analysis of 47 patients, the response rate to cytotoxic chemotherapy was 20/33 (62%) for ER+ tumors and 8/14 (57%) for ER-. It is concluded that ER+ tumors have a significantly higher chance of responding to endocrine therapy than do ER- tumors, but that receptor status is not a determinant of response to cytotoxic chemotherapy.Keywords
This publication has 7 references indexed in Scilit:
- Estrogen Receptors and Responses to Chemotherapy and Hormonal Therapy in Advanced Breast CancerNew England Journal of Medicine, 1978
- Combined cytotoxic and progestogen therapy for advanced breast cancerCancer, 1978
- Oestrogen receptors and the response to endocrine therapy in advanced breast cancerBritish Journal of Cancer, 1978
- The Relation between Estrogen Receptors and Response Rate to Cytotoxic Chemotherapy in Metastatic Breast CancerNew England Journal of Medicine, 1978
- Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, SwitzerlandCancer, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combinationBritish Journal of Cancer, 1975